Department of Pathology, AFMC, Pune, Maharashtra, India.
Department of Pathology, INHS, Asvini, Mumbai, India.
Indian J Pathol Microbiol. 2023 Apr-Jun;66(2):264-268. doi: 10.4103/IJPM.IJPM_1439_20.
High-grade glial tumors remain as one of the most lethal malignancies. Cyclin D1 is expressed in some human malignancies and is the potential target of intervention. The present study aims to determine the relationship of cyclin D1 expression with other clinicopathological parameters.
A cross-sectional study was carried out in a tertiary care center. Biopsy proven 66 cases of glial tumor patients were included in the study. The patients with incomplete clinical details were excluded from the study. Immunohistochemistry using antibodies for IDH 1 and cyclin d1 was done in all the cases. Glial tumors were reclassified according to WHO 2016 classification. Data analysis was performed using SPSS 26.0 for the windows.
Among 66 patients, 49 (74.3%) were males and 17 (25.7%) were females. The age of the patients ranged from 20 years to 70 years. Overall, 6.02% were of grade I Glial tumors, 22.7% were of grade II Glial tumors, 19.6% patients were of grade III Glial tumors, and 51.6% patients were of grade IV Glial tumors. Of 66 samples tested cyclin D1 was positive in 25 (37.87%) as high expressers and 7 (10.60%) were low expressers. Our study showed a significant correlation between the expression of cyclin D1 with grade and IDH mutation status, No significant correlation of cyclin D1 was noted with age or sex of the patient.
Cyclin D1 was associated with a higher grade of the glial tumor. It can be a potential marker both for prognosis and treatment of glial tumors.
高级别神经胶质瘤仍然是最致命的恶性肿瘤之一。细胞周期蛋白 D1 在一些人类恶性肿瘤中表达，是干预的潜在靶点。本研究旨在确定细胞周期蛋白 D1 表达与其他临床病理参数的关系。
在一家三级保健中心进行了一项横断面研究。纳入了 66 例经活检证实的神经胶质瘤患者。将临床资料不完整的患者排除在研究之外。所有病例均采用 IDH1 和 cyclin d1 抗体进行免疫组织化学染色。根据 2016 年世界卫生组织（WHO）分类对神经胶质瘤进行重新分类。使用 SPSS 26.0 for the windows 进行数据分析。
在 66 例患者中，男性 49 例（74.3%），女性 17 例（25.7%）。患者年龄为 20 岁至 70 岁。总体而言，6.02%为 I 级神经胶质瘤，22.7%为 II 级神经胶质瘤，19.6%为 III 级神经胶质瘤，51.6%为 IV 级神经胶质瘤。在 66 例检测的样本中，cyclin D1 阳性 25 例（37.87%）为高表达，7 例（10.60%）为低表达。我们的研究表明，cyclin D1 的表达与分级和 IDH 突变状态显著相关，与患者的年龄或性别无显著相关性。
cyclin D1 与神经胶质瘤的高级别相关。它可能是神经胶质瘤预后和治疗的潜在标志物。
